top of page
doctor and patient looking at phone.png

Transforming Multiple Myeloma Care Through Real-Time Symptom and Quality of Life Measurement

Join leading myeloma specialists exploring SMS-based PRO collection that achieves superior patient adherence compared to application-based approaches

Join us at the ASH Annual Meeting and Exposition from December 6-9, 2025, in Orlando, Florida.

Session Name: 907. Outcomes Research: Plasma Cell Disorders: Innovations in Myeloma: Therapy, Prevention & Patient-Centered Care

Session Date: December 6, 2025

Session Time: 4:00 PM - 5:30 PM

Presentation Time: 4:45 PM - 5:00 PM

Room: OCCC - West Hall E2

Publication Number: 406

Platform Overview

The Challenge

  • 40% PRO engagement

  • Missed symptoms

  • Delayed intervention

Our Solution

  • SMS-based tracking

  • Real-time alerts

  • EHR integration

Clinical Results

  • Significantly higher engagement

  • Earlier intervention 

  • Better outcomes

Research Highlights

01

Objectives

  • Co-Primaries

    • Feasibility: Evaluate patient adoption and platform accessibility

    • Engagement: Measure completion rates and participation frequency. 

  • Secondary: Time Burden Assess patient experience and efficiency

  • Exploratory: Clinical Utility Evaluate actionable event identification

Study Design

  • Single-center prospective observational study

  • Enrollment: March 2, 2025 through May 12, 2025

  • Follow-up: 90 days

  • Median time on study: 9 weeks

02

Methods

Study Design

  • Single-center prospective observational study

  • Enrollment: March 2, 2025 through May 12, 2025

  • Follow-up: 90 days

  • Median time on study: 9 weeks

Participants

  • 58 MM patients

  • Median age: 68.1 years (range 47-91)

  • Three cohorts: NDMM, RRMM; MAINT

03

Key Findings

Both symptom and QoL check-in completion rates approach 90% Success

 

Factors:

  • Intuitive interface with simplified text-based interactions

  • Minimal time burden supporting consistent patient engagement

  • SMS delivery eliminates app download requirement

  • Targeted questioning based on patient cohort and needs

Clinical Utility:

  • Early identification of symptom changes

  • Preventive intervention opportunities

  • Improved treatment side effect management

  • Enhanced patient-clinician communications

04

Conclusions

The mQOL platform demonstrated:

  • Excellent feasibility with nearly 90% completion rates

  • High patient adherence across all cohorts

  • Minimal response burden (<3 minutes per assessment)

  • Substantial clinical utility through early event identification

Real-time, patient-driven digital monitoring provides rapid, actionable insights into the MM treatment journey, supporting Patient Centered Outcomes

Get Early Access to mQOL Platform

Role
Institution Type
Primary Interest
Current PRO Methods

Your information is handled in accordance with HIPAA guidelines and will

only be used for mQOL product communications.

Bringing Value—Across the Board

For Clinicians

  • Proactive monitoring

  • Workflow integration

  • Evidence-based alerts

For Researchers

  • Rich datasets

  • Real-world evidence

  • EHR integration

For Health Systems

  • Significantly higher engagement

  • Earlier intervention 

  • Better outcomes

A Trusted Solution

100+ years combined healthcare experience

HIPAA-compliant SMS platform

Pursuing FDA Breakthrough Device status

Doctor and Patient
bottom of page